Abstract: Bridging therapy serves as an adjunctive treatment during chimeric antigen receptor T cell therapy (CAR-T) and is specifically implemented after the collection of mononuclear cells but before the subsequent infusion of CAR-T cells. This approach can mitigate the progression of large B-cell lymphoma (LBCL) to a certain extent, reduce tumor burden, and facilitate the infusion of CAR-T cells. Bridging therapy includes chemotherapy, radiation therapy, and targeted therapies and ensures effective reinfusion of CAR-T cells and enhances the therapeutic efficacy of CAR-T cells. This study systematically reviews the significance, methodologies, and characteristics of CAR-T-cell-related bridging therapy for large B-cell lymphoma to provide valuable references for its clinical application.